MabGenesis was newly listed on the TSE Growth Market today. The offer price was ¥830, the opening price was ¥763, and the share price on the second day after listing was ¥748, down from the offer price.
MabGenesis (653A) was newly listed on the TSE Growth Market, with an offer price of ¥830. The opening price was ¥763, attracting attention during trading on the first day of listing.
A review of the share price on the second day after listing shows it at ¥748, approximately 9.9% below the offer price of ¥830.
The public offering comprised approximately 2.29 million shares, with an absorption amount of approximately ¥1.9 billion. The supply of shares associated with the listing has been cited as a factor weighing on the upside.
MabGenesis listed as a company engaged in the research and development of antibody drugs for pets, and its future developments are attracting market attention.